Literature DB >> 10486177

The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.

T Alexi1, P E Hughes, W M van Roon-Mom, R L Faull, C E Williams, R G Clark, P D Gluckman.   

Abstract

Huntington's disease is an incurable genetic neurological disorder characterized by the relatively selective degeneration of the striatum. Lesioning of the striatum in rodents using the excitatory amino acid agonist, quinolinic acid (QA), effectively mimics the human neuropathology seen in Huntington's disease. Using this animal model of Huntington's disease, we investigated the ability of the insulin-like growth factor-I (IGF-I) amino-terminal tripeptide glycine-proline-glutamate (GPE) to protect striatal neurons from degeneration. Adult rats received a single unilateral intrastriatal injection of QA (100 nmol) and then daily injection of either vehicle or GPE (0.3 microgram/microliter/day) into the striatum for 7 days. QA at this dose resulted in a partial lesioning of the striatum after 7 days to approximately 50% of cells of unlesioned levels in vehicle-treated animals. The major striatal neuronal phenotype, GABAergic projection neurons, were identified by immunocytochemical labeling of either glutamate decarboxylase 67 (GAD(67)) or the calcium binding protein calbindin in alternate sections. Treatment with GPE for 7 days reversed the loss in projection neurons when assessed by counts of calbindin-stained cells; however, these rescued cells did not regain immunologically detectable levels of GAD(67). GPE also significantly reversed the phenotypic degeneration of cholinergic interneurons identified by immunolabeling for choline acetyltransferase (ChAT) and NADPH diaphorase interneurons identified histochemically. GPE treatment failed to rescue the calcium binding protein interneuron populations of parvalbumin and calretinin neurons. These findings reveal that exogenous administration of GPE selectively prevents excitotoxin induced phenotypic degeneration of striatal projection neurons and cholinergic and NADPH diaphorase interneurons in an animal model of Huntington's disease. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486177     DOI: 10.1006/exnr.1999.7168

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

1.  Glutamate-related gene expression changes with age in the mouse auditory midbrain.

Authors:  Sherif F Tadros; Mary D'Souza; Martha L Zettel; Xiaoxia Zhu; Nicole C Waxmonsky; Robert D Frisina
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

2.  IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice.

Authors:  Carla Lopes; Márcio Ribeiro; Ana I Duarte; Sandrine Humbert; Frederic Saudou; Luís Pereira de Almeida; Michael Hayden; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2013-12-18       Impact factor: 5.590

Review 3.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017

4.  Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide.

Authors:  Sook-Eun Park; Marcus Lawson; Robert Dantzer; Keith W Kelley; Robert H McCusker
Journal:  J Neuroinflammation       Date:  2011-12-21       Impact factor: 8.322

Review 5.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

Review 6.  Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition.

Authors:  Mohammad H Baig; Khurshid Ahmad; Gulam Rabbani; Inho Choi
Journal:  Front Aging Neurosci       Date:  2018-02-07       Impact factor: 5.750

7.  GPE Promotes the Proliferation and Migration of Mouse Embryonic Neural Stem Cells and Their Progeny In Vitro.

Authors:  Cristina Almengló; Pablo Devesa; Jesús Devesa; Víctor M Arce
Journal:  Int J Mol Sci       Date:  2017-06-16       Impact factor: 5.923

8.  NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats.

Authors:  Hans H Wei; Xi-Chun M Lu; Deborah A Shear; Anu Waghray; Changping Yao; Frank C Tortella; Jitendra R Dave
Journal:  J Neuroinflammation       Date:  2009-08-05       Impact factor: 8.322

9.  Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease.

Authors:  P Stepanova; V Srinivasan; D Lindholm; M H Voutilainen
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.